关键词: FDA, 医药产品, 紧急使用授权, 公共卫生事件

Abstract: Corona virus disease is an acute respiratory infectious disease caused by COVID-19. Due to lack of specific drugs, national and local research teams find some drugs with potential clinical efficacy on the basis of multiple rounds of drug screening. However, rigorous clinical trials and approval are still needed before the drugs come into the market. It is of great significance to explore the medication system under the condition of public health event .By analyzing and learning lessons from FDA's emergency use authorization of medical products , this paper proposes drug approval policy suggestions for national and provincial medical products administration when China face the challenge of public health events.

Key words: US FDA, Medical Products, Emergency Use Authorization, Public Health Event